Cencora strengthens pharmaceutical supply chain with expanded drug shortage mitigation program

Cencora, a leading global healthcare solutions company, has announced a major expansion of its drug shortage mitigation initiative, the sure supply program. This development is designed to address the growing issue of medication shortages across the United States by ensuring consistent access to critical drugs for health systems. The program’s significant growth, with a 350% increase in the number of available medications since its launch in 2021, highlights Cencora’s commitment to enhancing pharmaceutical supply chain resilience.

In response to the escalating frequency of drug shortages, Cencora’s sure supply program now includes nearly 200 medications, including life-saving oncology treatments. This initiative comes at a time when healthcare providers face mounting challenges in securing essential medications, impacting patient care and operational efficiency.

How is Cencora tackling drug shortages in the healthcare system?

Cencora’s sure supply program is a strategic response to the persistent issue of drug shortages that affect hospitals and health systems nationwide. According to industry data, more than 99% of hospital pharmacists reported drug shortages in 2023. These shortages often force healthcare providers to allocate additional resources, both administrative and financial, to source alternative therapies.

The sure supply program is specifically designed to mitigate these challenges by providing reliable access to a broad range of critical medications across various therapeutic areas, including oncology, critical care, cardiovascular health, and infectious diseases. By expanding the program’s reach, Cencora aims to stabilise the pharmaceutical supply chain, ensuring that health systems can maintain continuity of care without the constant threat of medication shortages.

One of the key differentiators of Cencora’s approach is the maintenance of a six-month safety stock of critical medications for health systems enrolled in the program. This safety stock is tailored to each system’s monthly purchasing commitments, offering a robust buffer against supply disruptions. The program’s expansion also includes long-term agreements with pharmaceutical manufacturers to produce new inventory, further strengthening the availability of essential medications.

What makes Cencora’s drug shortage mitigation program unique?

Unlike many traditional drug shortage mitigation strategies, which often rely on reactive measures, Cencora’s program is proactive. The company negotiates long-term contracts with manufacturers to ensure that additional inventory is produced specifically for the program. This strategy not only increases the quantity of medications in the pharmaceutical supply chain but also reduces the risk of supply gaps during periods of heightened demand or production disruptions.

Importantly, Cencora’s program only includes products that are in good supply and do not compromise manufacturers’ ability to meet broader market demands. This careful selection process ensures that the program supports supply chain stability without inadvertently causing shortages elsewhere.

Matt Glucksmann, Senior Vice President and President of Health Systems & Government Services at Cencora, emphasised the importance of reliable medication access. “No provider should have to delay or cancel critical treatments due to drug shortages. Our sure supply program is designed to provide consistent, dependable access to the medications healthcare providers need, exactly when they need them,” he stated.

How does the program support healthcare providers?

Cencora leverages its extensive distribution network to support the sure supply program. The six-month inventory of critical medications is stored at distribution centres strategically located near participating health systems. This proximity ensures that hospitals can access vital medications quickly, reducing the risk of treatment delays due to logistical challenges.

To maintain efficiency, Cencora closely monitors the utilisation of these medications, adjusting inventory levels based on real-time demand data. This approach helps to right-size stock levels, avoiding both shortages and excess supply. Within the past year alone, every health system enrolled in the program has accessed at least one product from their safety stock, demonstrating the program’s critical role in maintaining uninterrupted patient care.

Austin Pytlowany, Clinical Pharmacist Specialist in Drug Shortage Management at the University of Michigan Health System, praised the program’s effectiveness. “The sure supply program has been instrumental in helping our health system navigate severe national drug shortages. It gives us peace of mind knowing that we can continue to provide uncompromised care to our patients, even when broader supply chains are under strain,” he said.

Why are drug shortages becoming more common, and how is Cencora addressing this trend?

Drug shortages are often the result of complex, interconnected factors, including manufacturing disruptions, supply chain bottlenecks, regulatory hurdles, and fluctuations in raw material availability. The increasing frequency of these shortages highlights the need for innovative, collaborative solutions that address not just the symptoms but also the root causes of supply chain vulnerabilities.

Cencora’s sure supply program represents a comprehensive approach to this challenge. By partnering with both public and private sector stakeholders, the company is working to create a more resilient pharmaceutical supply chain. This includes advocating for regulatory reforms that streamline production processes, investing in supply chain infrastructure, and fostering stronger relationships with manufacturers to ensure consistent medication availability.

As part of its broader strategy, Cencora is also focused on data-driven decision-making. The company utilises advanced analytics to forecast demand trends, identify potential supply chain risks, and optimise inventory management. This proactive approach allows Cencora to anticipate shortages before they occur, providing health systems with the stability they need to focus on patient care.

What’s next for Cencora’s supply chain resilience efforts?

Cencora’s commitment to strengthening the pharmaceutical supply chain extends beyond the sure supply program. The company continues to explore new initiatives aimed at addressing systemic challenges within the healthcare industry. This includes expanding partnerships with key stakeholders, investing in innovative technologies, and developing policies that promote supply chain resilience on a national and global scale.

As drug shortages become an increasingly common issue, programs like Cencora’s sure supply initiative will play a critical role in safeguarding public health. Through strategic collaboration, forward-thinking policies, and a relentless focus on innovation, Cencora is positioning itself as a leader in the fight against medication shortages.

For healthcare providers, patients, and the broader community, this means greater confidence in the availability of life-saving medications, even in the face of unprecedented supply chain challenges.